Cholesterol drug tested to stop stroke worsening
NCT ID NCT07301372
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving the cholesterol-lowering drug evolocumab within 24 hours after clot-busting treatment (thrombolysis) can prevent early neurological decline in people with acute ischemic stroke. 132 participants were randomly assigned to receive evolocumab plus standard care or standard care alone. The main goal was to see if evolocumab reduced worsening of stroke symptoms in the first week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- evolocumab (a cholesterol-lowering drug)
- What this could lead to
- If it works, this could point toward a way to prevent early neurological decline after a stroke, potentially improving recovery.
- What could go wrong
- This is a small, single-center, open-label trial, so results may not be definitive or apply broadly. The drug also does not eliminate the need for ongoing statin therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE DUE TO LARGE ARTERY ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Neurology
Xuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- A Pocket-Sized MRI for strokes? new device put to the test
- Does a dedicated stroke unit boost recovery after a first stroke?
- Could inflammation after stroke trigger depression?
- Pocket-Sized MRI could spot strokes at bedside
- Could common drugs curb brain bleed aftermath?